Burzynski: VISUAL (OPTIC) PATHWAY GLIOMA (TUMORS)

� � � � � � � � � � � � � � � � �
# and % of Patients Resolving or Stabilizing Disease = Complete Response + Partial Response + Stable Disease
——————————————————————
11 / 92% – 6/2008 Antineoplastons – Protocol – CHILDREN WITH optic PATHWAY GLIOMA (OPG)

11 / 91% –
Antineoplastons: young children with progressive OPTIC PATHWAY TUMORS

16 / 80% – 2004 Chemotherapy: Protocol Bouffet E, Goldman S, Jakacki R, et al. Pilot study of vinblastine in patients with recurrent and refractory low-grade glioma [abstract]. Neuro-oncol 2004; 6: 450 (Pg. 170 + 175) Optic Pathway Gliomas 2006

39 / 78% – 10/2000 – Protocol – solitary progressive OPTIC PATHWAY TUMORS with carboplatin: The Pediatric Oncology Group

7 / 64% – Mamelak et al

15 / 62.5% – 2004 Chemotherapy / Targeted Therapy: Gnekow AK, Kortmann RD, Pietsch T, et al. Low-grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy: report from the multicenter treatment study for children and adolescents with a low grade glioma: HIT-LGG 1996. Society of Pediatric Oncology and Hematology (GPOH). Klin Padiatr 2004; 216: 331-42 (Pgs. 171 + 176) LOW-GRADE GLIOMA IN CHILDREN – Protocol Treatments for Astrocytic Tumors – Optical Pathway Glioma (OPG) Dactinomycin / Vincristine 2006

8 / 57% – Chamberlain and Grafe
======================================
# and % of Patients Showing Objective Response = Complete Response + Partial Response
——————————————————————
7 / 58% – Antineoplastons: young children with progressive OPTIC PATHWAY TUMORS

58 / 51% – 2004 Chemotherapy / Targeted Therapy – Protocol: Gnekow AK, Kortmann RD, Pietsch T, et al. Low-grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy : report from the multicenter treatment study for children and adolescents with a low grade glioma: HIT-LGG 1996. Society of Pediatric Oncology and Hematology (GPOH). Klin Pediatr 2004; 216: 331-42 Treatments for Astrocytic Tumors – Optical Pathway Glioma (OPG) LOW-GRADE GLIOMA IN CHILDREN (Pgs. 171 + 176) Vincristine /Carboplatin 2006

5 / 42% – 6/2008 Antineoplastons – Protocol – CHILDREN WITH optic PATHWAY GLIOMA (OPG)

5 / 36% – Chamberlain and Grafe

4 / 20% – 2004 Chemotherapy: Protocol Bouffet E, Goldman S, Jakacki R, et al. Pilot study of vinblastine in patients with recurrent and refractory low-grade glioma [abstract]. Neuro-oncol 2004; 6: 450 (Pg. 170 + 175) Optic Pathway Gliomas 2006

2 / 18% – Mamelak et al

3 / 12.5% – 2004 Chemotherapy / Targeted Therapy: Gnekow AK, Kortmann RD, Pietsch T, et al. Low-grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy: report from the multicenter treatment study for children and adolescents with a low grade glioma: HIT-LGG 1996. Society of Pediatric Oncology and Hematology (GPOH). Klin Padiatr 2004; 216: 331-42 (Pgs. 171 + 176) LOW-GRADE GLIOMA IN CHILDREN – Protocol Treatments for Astrocytic Tumors – Optical Pathway Glioma (OPG) Dactinomycin / Vincristine 2006

2 / 4% – 10/2000 – Protocol – solitary progressive OPTIC PATHWAY TUMORS with carboplatin: The Pediatric Oncology Group
======================================
# and % of Patients Showing Complete Response
——————————————————————
4 / 33% – Antineoplastons: young children with progressive OPTIC PATHWAY TUMORS

3 / 25% – 6/2008 Antineoplastons – Protocol – CHILDREN WITH optic PATHWAY GLIOMA (OPG)

2 / 18% – # and % of Patients Showing Remission (definition of remission wasn’t provided)
Mamelak et al.

1 / 7% – Chamberlain and Grafe

0 / 0% – 2004 Chemotherapy: Protocol Bouffet E, Goldman S, Jakacki R, et al. Pilot study of vinblastine in patients with recurrent and refractory low-grade glioma [abstract]. Neuro-oncol 2004; 6: 450 (Pg. 170 + 175) Optic Pathway Gliomas 2006
======================================
# and % of Patients Showing Partial Response
——————————————————————
58 / 51% – 2004 Chemotherapy / Targeted Therapy – Protocol: Gnekow AK, Kortmann RD, Pietsch T, et al. Low-grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy : report from the multicenter treatment study for children and adolescents with a low grade glioma: HIT-LGG 1996. Society of Pediatric Oncology and Hematology (GPOH). Klin Pediatr 2004; 216: 331-42 Treatments for Astrocytic Tumors – Optical Pathway Glioma (OPG) LOW-GRADE GLIOMA IN CHILDREN (Pgs. 171 + 176) Vincristine /Carboplatin 2006

4 / 29% – Chamberlain and Grafe

3 / 25% – Antineoplastons: young children with progressive OPTIC PATHWAY TUMORS

4 / 20% – 2004 Chemotherapy: Protocol Bouffet E, Goldman S, Jakacki R, et al. Pilot study of vinblastine in patients with recurrent and refractory low-grade glioma [abstract]. Neuro-oncol 2004; 6: 450 (Pg. 170 + 175) Optic Pathway Gliomas 2006

2 / 18% – # and % of Patients Showing Remission (definition of remission wasn’t provided)
Mamelak et al

2 / 17% – 6/2008 Antineoplastons – Protocol – CHILDREN WITH optic PATHWAY GLIOMA (OPG)

3 / 12.5% – 2004 Chemotherapy / Targeted Therapy: Gnekow AK, Kortmann RD, Pietsch T, et al. Low-grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy: report from the multicenter treatment study for children and adolescents with a low grade glioma: HIT-LGG 1996. Society of Pediatric Oncology and Hematology (GPOH). Klin Padiatr 2004; 216: 331-42 (Pgs. 171 + 176) LOW-GRADE GLIOMA IN CHILDREN – Protocol Treatments for Astrocytic Tumors – Optical Pathway Glioma (OPG) Dactinomycin / Vincristine 2006

2 / 4% – 10/2000 – Protocol – solitary progressive OPTIC PATHWAY TUMORS with carboplatin: The Pediatric Oncology Group
======================================
# and % of Patients Showing Stable Disease
——————————————————————
37 / 74% – 10/2000 – Protocol – solitary progressive OPTIC PATHWAY TUMORS with carboplatin: The Pediatric Oncology Group

12 / 60% – 2004 Chemotherapy: Protocol Bouffet E, Goldman S, Jakacki R, et al. Pilot study of vinblastine in patients with recurrent and refractory low-grade glioma [abstract]. Neuro-oncol 2004; 6: 450 (Pg. 170 + 175) Optic Pathway Gliomas 2006

6 / 50% – 6/2008 Antineoplastons – Protocol – CHILDREN WITH optic PATHWAY GLIOMA (OPG)

12 / 50% – 2004 Chemotherapy / Targeted Therapy: Gnekow AK, Kortmann RD, Pietsch T, et al. Low-grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy: report from the multicenter treatment study for children and adolescents with a low grade glioma: HIT-LGG 1996. Society of Pediatric Oncology and Hematology (GPOH). Klin Padiatr 2004; 216: 331-42 (Pgs. 171 + 176) LOW-GRADE GLIOMA IN CHILDREN – Protocol Treatments for Astrocytic Tumors – Optical Pathway Glioma (OPG) Dactinomycin / Vincristine 2006

5 / 46% – Mamelak et al

46 / 41% – 2004 Chemotherapy / Targeted Therapy – Protocol: Gnekow AK, Kortmann RD, Pietsch T, et al. Low-grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy : report from the multicenter treatment study for children and adolescents with a low grade glioma: HIT-LGG 1996. Society of Pediatric Oncology and Hematology (GPOH). Klin Pediatr 2004; 216: 331-42 Treatments for Astrocytic Tumors – Optical Pathway Glioma (OPG) LOW-GRADE GLIOMA IN CHILDREN (Pgs. 171 + 176) Vincristine /Carboplatin 2006
=====================================

4 / 33% – Antineoplastons: young children with progressive OPTIC PATHWAY TUMORS

3 / 21% – Chamberlain and Grafe
======================================
# and % of Patients Showing Progressive Disease
——————————————————————
0 / 0% – Antineoplastons: young children with progressive OPTIC PATHWAY TUMORS

9 / 8% – 2004 Chemotherapy / Targeted Therapy – Protocol: Gnekow AK, Kortmann RD, Pietsch T, et al. Low-grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy : report from the multicenter treatment study for children and adolescents with a low grade glioma: HIT-LGG 1996. Society of Pediatric Oncology and Hematology (GPOH). Klin Pediatr 2004; 216: 331-42
Treatments for Astrocytic Tumors – Optical Pathway Glioma (OPG) LOW-GRADE GLIOMA IN CHILDREN (Pgs. 171 + 176) Vincristine /Carboplatin 2006

1 / 8% – 6/2008 Antineoplastons – Protocol – CHILDREN WITH optic PATHWAY GLIOMA (OPG)

4 / 20% – 2004 Chemotherapy: Protocol – Bouffet E, Goldman S, Jakacki R, et al. Pilot study of vinblastine in patients with recurrent and refractory low-grade glioma [abstract]. Neuro-oncol 2004; 6: 450 (Pg. 170 + 175) Optic Pathway Gliomas 2006

11 / 22% – 10/2000 – Protocol – solitary progressive OPTIC PATHWAY TUMORS with carboplatin: The Pediatric Oncology Group

4 / 36% – # and % of Patients Died
Mamelak et al

9 / 37.5% – 2004 Chemotherapy / Targeted Therapy: Gnekow AK, Kortmann RD, Pietsch T, et al. Low-grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy: report from the multicenter treatment study for children and adolescents with a low grade glioma: HIT-LGG 1996. Society of Pediatric Oncology and Hematology (GPOH). Klin Padiatr 2004; 216: 331-42 (Pgs. 171 + 176) LOW-GRADE GLIOMA IN CHILDREN – Protocol Treatments for Astrocytic Tumors – Optical Pathway Glioma (OPG) Dactinomycin / Vincristine 2006

6 / 43% – Chamberlain and Grafe
=====================================
Developed Progression:
——————————————————————
47 / 42% – 2004 Chemotherapy / Targeted Therapy – Protocol: Gnekow AK, Kortmann RD, Pietsch T, et al. Low-grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy : report from the multicenter treatment study for children and adolescents with a low grade glioma: HIT-LGG 1996. Society of Pediatric Oncology and Hematology (GPOH). Klin Pediatr 2004; 216: 331-42
Treatments for Astrocytic Tumors – Optical Pathway Glioma (OPG) LOW-GRADE GLIOMA IN CHILDREN (Pgs. 171 + 176) 2006
=====================================
Median Time to Progression (MTP):
——————————————————————
22.5 months (1 year 10.5 months) –
2004 Chemotherapy / Targeted Therapy – Protocol: Gnekow AK, Kortmann RD, Pietsch T, et al. Low-grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy : report from the multicenter treatment study for children and adolescents with a low grade glioma: HIT-LGG 1996. Society of Pediatric Oncology and Hematology (GPOH). Klin Pediatr 2004; 216: 331-42
Treatments for Astrocytic Tumors – Optical Pathway Glioma (OPG) LOW-GRADE GLIOMA IN CHILDREN (Pgs. 171 + 176) 2006
� � � � � � � � � � � � � � � � �

� � � � � � � � � � � � � � � � �
Alive and Well from 2 to >14 years Post-Diagnosis:
——————————————————————
10 – 2004 Antineoplastons: children with recurrent and progressive MULTICENTRIC GLIOMA (Pgs. 315-317 and 320-321)
======================================
Alive and Well from 2 to >14 years Post-Diagnosis:
——————————————————————
10 / 100% – 10/2003 Antineoplastons: Protocol – MULTICENTRIC GLIOMA
======================================
# and % of Patients Alive and Well (2 to 13 years Post Diagnosis):
——————————————————————
10 / 100% – 10/2003 Antineoplastons: Protocol – MULTICENTRIC GLIOMA
======================================
Median Survival Post Diagnosis:
——————————————————————
7 years approximately – Antineoplastons: (7/31/1996–4/3/2002 as of 3/1/2004) Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA (MCG) (Pgs. 317 and 320-321) 3 – treated under Special Exception (SE) granted by the US FDA (Pg. 320) (Pgs. 315 and 320-321)
======================================
Median Overall Survival from Diagnosis (OSD):
——————————————————————
6.3 years – 6/1/2003 Antineoplastons: Protocols – LOW-GRADE GLIOMA IN CHILDREN 2004 (Pg. 50)
======================================
Projected 70 month (5 years 10 months) event-free survival:
——————————————————————
2.5% – 1988 Chemotherapy / Targeted Therapy – Protocol: Packer RJ, Sutton LN, Bilaniuk LT, et al. Treatment of chiasmatic/hypothalamic gliomas of childhood with chemotherapy: an update. Ann Neurol 1988; 23: 79-85 Treatments for Astrocytic Tumors – Optical Pathway Glioma (OPG) (Pgs. 171 + Pg. 176) 2006
======================================
Median Overall Survival Post Diagnosis from initiation of Antineoplastons (ANP) with studies still ongoing:
——————————————————————
5 years – Antineoplastons: (7/31/1996–4/3/2002 as of 3/1/2004) Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA (MCG) (Pgs. 317 and 320-321) 3 – treated under Special Exception (SE) granted by the US FDA (Pg. 320) (Pgs. 315 and 320-321)
======================================
Median Progression-Free Survival (PFS):
——————————————————————
5 years – Antineoplastons: (7/31/1996–4/3/2002 as of 3/1/2004) Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA (MCG) (Pgs. 317 and 320-321) 3 – treated under Special Exception (SE) granted by the US FDA (Pg. 320) (Pgs. 315 and 320-321)
======================================
Median Survival:
——————————————————————
4.3 year – 1988 Chemotherapy / Targeted Therapy – Protocol: Packer RJ, Sutton LN, Bilaniuk LT, et al. Treatment of chiasmatic/hypothalamic gliomas of childhood with chemotherapy: an update. Ann Neurol 1988; 23: 79-85 Treatments for Astrocytic Tumors – Optical Pathway Glioma (OPG) (Pgs. 171 + Pg. 176) 2006
======================================
Overall Survival (OS):
——————————————————————
10 / 100% – 2006 Antineoplastons (ANP) Protocol LOW-GRADE GLIOMA IN CHILDREN (Pg. 170 + 175) Optic Pathway Gliomas
======================================
# and % of Patients Showing Progressive Disease:
——————————————————————
0 / 0% – Antineoplastons: (7/31/1996–4/3/2002 as of 3/1/2004) Protocol – children with recurrent and progressive MULTICENTRIC GLIOMA (MCG) (Pgs. 317 and 320-321) 3 – treated under Special Exception (SE) granted by the US FDA (Pg. 320) (Pgs. 315 and 320-321)
� � � � � � � � � � � � � � � � �

� � � � � � � � � � � � � � � � �
Burzynski: Complete Response, Partial Response, Stable Disease, Progressive Disease, Objective Response, and Response:
https://stanislawrajmundburzynski.wordpress.com/2013/07/04/burzynski-complete-response-partial-response-stable-disease-progressive-disease-objective-response-and-response/
� � � � � � � � � � � � � � � � �
Burzynski: Progression-Free Survival:
https://stanislawrajmundburzynski.wordpress.com/2013/07/04/burzynski-progression-free-survival/
� � � � � � � � � � � � � � � � �

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s